Filana Therapeutics/$FLNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Filana Therapeutics
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Ticker
$FLNA
Sector
Primary listing
Employees
19
Headquarters
Website
FLNA Metrics
BasicAdvanced
$58m
-
-$1.61
-0.78
-
Price and volume
Market cap
$58m
Beta
-0.78
52-week high
$4.98
52-week low
$1.16
Average daily volume
373k
Financial strength
Current ratio
2.193
Quick ratio
2.158
Profitability
EBITDA (TTM)
-48.713
Management effectiveness
Return on assets (TTM)
-24.91%
Return on equity (TTM)
-79.59%
Valuation
Price to book
0.86
Price to tangible book (TTM)
0.86
Price to free cash flow (TTM)
-1.924
Free cash flow yield (TTM)
-51.96%
Free cash flow per share (TTM)
-0.629
Growth
Earnings per share change (TTM)
5.55%
3-year earnings per share growth (CAGR)
-7.56%
10-year earnings per share growth (CAGR)
-4.95%
What the Analysts think about FLNA
Analyst ratings (Buy, Hold, Sell) for Filana Therapeutics stock.
FLNA Financial Performance
Revenues and expenses
FLNA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs